Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 1:48 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2929–2952 of 7,489 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Standard Control Clear all

Conditions: Epilepsy
Interventions: Activity Tracker Group, Standard of Care Group; Behavioral
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years to 64 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Infertility
Interventions: Low dose hCG plus FSH co-trigger, Standard dose of hCG; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 41 Years · Female only
Enrollment: 105 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Mental Health, Psychological Well Being, Adolescent Health, Help-Seeking Behavior
Interventions: Meet Me on the Pitch (MMotP); Behavioral
Lead sponsor: University of California, San Francisco; Other
Eligibility: 14 Years to 21 Years
Enrollment: 480 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 2
States / cities: Oakland, California • Denver, Colorado

Conditions: Necrotizing Enterocolitis, Intra-abdominal Infection
Interventions: meropenem; Drug
Lead sponsor: The Emmes Company, LLC; Industry
Eligibility: Up to 90 Days
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 26
States / cities: Birmingham, Alabama • Oakland, California • Orange, California + 21 more

Conditions: Infertility
Interventions: Menopur, Synarel, HCG trigger, Clomiphene citrate, Letrozole; Drug
Lead sponsor: New Hope Fertility Center; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 4 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: New York, New York

Conditions: Optic, Atrophy, Hereditary, Leber
Interventions: GS010, Sham Intravitreal Injection; Biological · Device
Lead sponsor: GenSight Biologics; Industry
Eligibility: 15 Years and older
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 3
States / cities: Los Angeles, California • Atlanta, Georgia • Philadelphia, Pennsylvania

Conditions: Coronary Artery Disease, Ischemic Heart Disease (IHD), Myocardial Viability
Interventions: Not listed
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 20 Years to 80 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Depression, Bipolar Disorder, Psychosis, Anxiety Disorders
Interventions: Just Do You, Active Control; Behavioral
Lead sponsor: New York University; Other
Eligibility: 18 Years to 28 Years
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: New York, New York

Conditions: Asthma
Interventions: fluticasone, Standard Asthma Discharge Instructions; Drug · Other
Lead sponsor: Rhode Island Hospital; Other
Eligibility: 3 Years to 12 Years
Enrollment: 118 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Age Related Macular Degeneration
Interventions: Ranibizumab, Bevacizumab, Aflibercept, Control Group; Drug · Other
Lead sponsor: East Florida Eye Institute; Other
Eligibility: 50 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Stuart, Florida

Conditions: Sleep Initiation and Maintenance Disorders, Insomnia, Insomnia Chronic, Mindfulness, Telemedicine
Interventions: Instructed bedtime app-guided mindfulness meditation, Uninstructed app-guided mindfulness meditation, Sleep hygiene education; Behavioral
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Neonatal Hypoxic Ischemic Encephalopathy
Interventions: infusion of autologous cord blood, Neurodevelopmental outcomes; Biological · Other
Lead sponsor: Michael Cotten; Other
Eligibility: Up to 14 Days
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2017
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Health Maintenance
Interventions: Behaviorally informed tickler email; Behavioral
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years and older
Enrollment: 176,785 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: BRAF V600E-mutant Metastatic Colorectal Cancer
Interventions: Encorafenib, Binimetinib, Cetuximab, Irinotecan, Folinic Acid, 5-Fluorouracil; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 702 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 90
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Duarte, California + 45 more

Conditions: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Indolent Non-hodgkin Lymphoma
Interventions: Biospecimen Collection, Cardiopulmonary Exercise Testing, Dual X-ray Absorptiometry, Electronic Health Record Review, Exercise Intervention, Physical Examination, Questionnaire Administration, Spirometry, Physical Performance Testing, Best Practice; Procedure · Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 80 Years
Enrollment: 70 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2028
U.S. locations: 2
States / cities: Scottsdale, Arizona • Rochester, Minnesota

Conditions: Pain
Interventions: Google Cardboard VRA, Oculus Rift VRA; Other
Lead sponsor: Montefiore Medical Center; Other
Eligibility: 5 Years to 18 Years
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Transplant-Related Hematologic Malignancy
Interventions: Sargramostim, Control Arm; Drug · Other
Lead sponsor: Northside Hospital, Inc.; Other
Eligibility: 18 Years to 78 Years
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Severe Sepsis, Septic Shock
Interventions: Pioglitazone hydrochloride; Drug
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: Not listed
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Opioid Prescribing
Interventions: Usual Care, Opioid Stewardship Intervention; Other · Behavioral
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 2
States / cities: Chapel Hill, North Carolina • Wilmington, North Carolina

Conditions: Wound Infection
Interventions: PO versus IV antibiotics Route of administration evaluation; Other
Lead sponsor: Major Extremity Trauma Research Consortium; Other
Eligibility: 18 Years to 84 Years
Enrollment: 233 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2020
U.S. locations: 24
States / cities: Birmingham, Alabama • Los Angeles, California • San Francisco, California + 21 more

Conditions: Head and Neck Cancer (H&N)
Interventions: Standard Closure (Control), Avive+ Intervention; Procedure
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Growth Hormone Deficiency
Interventions: TV-1106, Placebo; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015
U.S. locations: 25
States / cities: Artesia, California • Fountain Valley, California • Miami, Florida + 15 more

Conditions: Premature Birth
Interventions: Language Treatment, Control Treatment; Behavioral
Lead sponsor: Stanford University; Other
Eligibility: 24 Weeks to 31 Weeks
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Gram-negative Bacterial Infections, Hospital Acquired Bacterial Pneumonia (HABP), Complicated Urinary Tract Infection (cUTI), Ventilator Associated Bacterial Pneumonia (VABP)
Interventions: Cefiderocol, Standard of Care; Drug
Lead sponsor: Shionogi; Industry
Eligibility: 3 Months to 17 Years
Enrollment: 91 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 2
States / cities: Iowa City, Iowa • Fort Worth, Texas

Search by objective public record fields.

Utilizing Activity Trackers to Promote Physical Activity in People With Epilepsy: Can we Make a Difference?

Administration of Follicle-stimulating Hormone (FSH) and Low Dose Human Chorionic Gonadotropin (hCG) for Oocyte Maturity While Decreasing hCG Exposure in In Vitro Fertilization (IVF) Cycles

Meet Me on the Pitch: Developing and Testing a Community-Based Sports and Behavioral Health Intervention for Youth

Pharmacokinetic (PK) and Safety Study of Meropenem in Young Infants With Intra-abdominal Infections

Protocol to Minimize Injections and Blood Draws for Women Undergoing in Vitro Fertilization

Efficacy Study of GS010 for the Treatment of Vision Loss up to 6 Months From Onset in LHON Due to the ND4 Mutation

Prognostic Value of Hyperpolarized 13C MRI for Clinical Myocardial Viability

Just Do You Program for Young Adults With Serious Mental IIlness

Inhaled Steroids at Discharge After Emergency Department Visits for Children With Uncontrolled Asthma

Comparison of Pharmacokinetics of and Effect on Systemic VEGF Levels in Age Related Macular Degeneration Patients

Mindfulness Meditation for Insomnia

Cord Blood for Neonatal Hypoxic-ischemic Encephalopathy

UCLA Health Patient Health Tickler Email

Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer

The Effects of Exercise on Immune Phenotype of Indolent Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia Patients

Assessing the Efficacy of Virtual Reality Analgesia (VRA) in Pediatric Patients for Pain Control

GM-CSF With Post-Transplant Cyclophosphamide

Pharmacokinetic and Biomarker Study of Pioglitazone in Adolescents With Severe Sepsis and Septic Shock

Reducing Post-Operative Opioid Prescribing in Southeastern North Carolina

Randomized Trial to Assess PO Versus IV Antibiotics

Evaluating Avive+ Soft Tissue Matrix for Prevention of Superficial Radial Nerve Morbidity Following Radial Forearm Free Flap Harvest

Study of TV-1106 in Growth Hormone-Deficient Adults

Listening to Mom in the NICU: Neural, Clinical and Language Outcomes

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Cefiderocol in Hospitalized Pediatric Participants